Before the GLP-1 boom of recent years, the pharmaceutical industry had begun to shift away from blockbuster drugs towards ...

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, entered a global research and licensing ...

Under the agreement Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to ...

Lilly gains worldwide exclusive rights to MeiraGTx AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4.

Eli Lilly and Co. has appointed two new Executive Committee members and has expanded other senior leaders’ roles to support the company in its next wave of growth.

Stewart will lead integration of technology and process transformation initiatives across Avid's development and manufacturing network.

Simtra BioPharma Solutions is advancing a dual-continent expansion aimed at boosting capacity for sterile injectable drugs.

Harbour BioMed, a global biopharmaceutical company, and Evinova, a global health-tech company, have entered a strategic ...

The U.S. Food and Drug Administration approved Johnson & Johnson’s drug Darzalex Faspro as the first treatment for adults with high-risk smoldering multiple myeloma, a precursor to the blood cancer.

Agreement expands Piramal’s payload-linker platform and bioconjugate abilities.

CEO shares insight on supply chain strategy and efficiency from drug development through to commercialization.

Account Executive shares insight on packaging trends and the capabilities needed to bring drugs to market faster.